GlassScriptPhysician profile
Shrenika Reddy
NPI 1801258207
$8,814.28
in general payments reported to CMS, 2019-2025
42 companies · $2,184 in 2025
The $2,184 reported for 2025 was more than what 78% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.23 · 2022: $2,357 · 2023: $2,782 · 2024: $1,455 · 2025: $2,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,301 · Education: $60.38 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,301.45 |
| Education | $60.38 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $876.10 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Mannkind Corporation | $752.98 | 2022-2025 | Afrezza |
| Medtronic, INC. | $639.25 | 2021-2025 | Minimed 780g, Minimed 770g, Intellis Adaptivestim |
| Corcept Therapeutics | $633.37 | 2022-2025 | Korlym |
| Lilly USA, LLC | $581.34 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $513.97 | 2022-2025 | Evenity, Repatha, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $486.43 | 2022-2025 | Jardiance, Synjardy |
| Dexcom, INC. | $392.76 | 2022-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $373.16 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $350.46 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $325.53 | 2023-2024 | |
| Xeris Pharmaceuticals, INC. | $283.41 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Insulet Corporation | $228.48 | 2023-2025 | Omnipod |
| Recordati_rare_diseases_inc. | $225.39 | 2024-2025 | Isturisa, Signifor Lar |
| Radius Health, INC. | $223.11 | 2022-2025 | Tymlos |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $217.67 | 2022-2024 | Senza |
| Abbott Laboratories | $163.80 | 2023-2025 | Freestyle Libre 3 |
| Alexion Pharmaceuticals, INC. | $131.95 | 2022-2025 | Strensiq |
| Amphastar Pharmaceuticals, INC. | $128.51 | 2023-2025 | Baqsimi |
| Ucb, INC. | $120.08 | 2022-2023 | Cimzia |
| Antares Pharma, INC. | $117.56 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Tandem Diabetes Care, INC. | $110.34 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascendis Pharma Endocrinology INC | $90.23 | 2024-2025 | Yorvipath |
| Sequel Med Tech, LLC | $83.31 | 2025 | Twiist |
| Beta Bionics, INC. | $82.72 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Kyowa Kirin, INC. | $71.18 | 2024-2025 | Crysvita |
| Averitas Pharma INC. | $63.72 | 2024 | Qutenza |
| Janssen Biotech, INC. | $55.34 | 2022 | |
| Horizon Therapeutics Plc | $51.64 | 2022-2023 | Tepezza |
| Currax Pharmaceuticals LLC | $50.00 | 2023 | Nexletol |
| Mallinckrodt Hospital Products INC. | $47.87 | 2022 | |
| Abbvie INC. | $44.24 | 2025 | |
| Madrigal Pharmaceuticals | $41.48 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $35.84 | 2022 | |
| Globus Medical, INC. | $35.65 | 2025 | Senza |
| Ascensia Diabetes Care US INC. | $32.19 | 2023 | |
| Halozyme INC | $30.91 | 2023 | |
| Amneal Pharmaceuticals LLC | $30.71 | 2022-2025 | Unithroid |
| Amarin Pharma, INC. | $29.50 | 2022 | |
| Echosens North America, INC. | $25.00 | 2025 | Fibroscan |
| Acella Pharmaceuticals, LLC | $18.76 | 2025 | NP Thyroid 60 |
| Neurocrine Biosciences, INC. | $18.34 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shrenika Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.